Principal Investigator
Peter Hosein
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20250964
Clinical Trial Summary
RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients with Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Phase
Phase III
Funding Agency/Sponsor
Industrial
Disease
Stomach and Esophageal Cancer
Contact Information
Phone Number
305-243-2647